Nano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy

• Published in: Cells (Basel, Switzerland) Vol. 10; no. 7; p. 1684
• Main Authors: Cheng, Tsai-Mu, Chang, Wong-Jin, Chu, Hsiu-Yi, De Luca, Roberto, Pedersen, Jens Z., Incerpi, Sandra, Li, Zi-Lin, Shih, Ya-Jung, Lin, Hung-Yun, Wang, Kuan, Whang-Peng, Jacqueline
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 03.07.2021; MDPI
• Subjects: Cancer therapies; Carcinoembryonic antigen; Cell adhesion molecules; Cell growth; Cell proliferation; Cell surface; drug-delivery system; Hormones; integrin αvβ3; Kinases; Metastases; nanomaterial; Nanomaterials; NDAT; Polylactide-co-glycolide; Potentiation; Resveratrol; Review; RGD; Signal transduction; Therapeutic applications; Thyroid cancer; trans-Stilbene
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells10071684

Integrin αvβ3, a cell surface receptor, participates in signaling transduction pathways in cancer cell proliferation and metastasis. Several ligands bind to integrin αvβ3 to regulate proliferation and metastasis in cancer cells. Crosstalk between the integrin and other signal transduction pathways also plays an important role in modulating cancer proliferation. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) activates the downstream integrin FAK to stimulate biological activities including cancer proliferation and metastasis. Blockage of signals related to integrin αvβ3 was shown to be a promising target for cancer therapies. 3,3′,5,5′-tetraiodothyroacetic acid (tetrac) completely binds to the integrin with the thyroid hormone to suppress cancer proliferation. The (E)-stilbene analog, resveratrol, also binds to integrin αvβ3 to inhibit cancer growth. Recently, nanotechnologies have been used in the biomedical field for detection and therapeutic purposes. In the current review, we show and evaluate the potentiation of the nanomaterial carrier RGD peptide, derivatives of PLGA-tetrac (NDAT), and nanoresveratrol targeting integrin αvβ3 in cancer therapies.